Primary outcome switching among drug trials with and without principal investigator financial ties to industry: A cross-sectional study

BMJ Open

Volumn 8, Issue 2, 2018, Pages

  Jones, Christopher W ^a   Misemer, Benjamin S ^a   Platts Mills, Timothy F ^b   Ahn, Rosa ^c   Woodbridge, Alexandra ^d   Abraham, Ann ^e   Saba, Susan ^e   Korenstein, Deborah ^f   Madden, Erin ^e   Keyhani, Salomeh ^g  

^a Cooper Medical School of Rowan University ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clinicaltrials.gov; conflict of interest; trial registration

Indexed keywords

ARTICLE; AUTHOR; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUSTRY; DRUG MANUFACTURE; FINANCIAL MANAGEMENT; FINANCIAL TIES; HUMAN; MEDLINE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; PUBLICATION; QUALITY CONTROL; REGISTRATION; SAMPLE SIZE; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; STUDY DESIGN; CONFLICT OF INTEREST; ECONOMICS; PERSONNEL; REGISTER; RESEARCH; RESEARCH ETHICS; STATISTICAL MODEL;

CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; ETHICS, RESEARCH; HUMANS; LOGISTIC MODELS; REGISTRIES; RESEARCH PERSONNEL; RESEARCH REPORT; RESEARCH SUPPORT AS TOPIC;

EID: 85052166902     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-019831     Document Type: Article

References (25)

1. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-5.
2. Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ 2017;356:i6770.
3. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
4. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturersupported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
5. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;190:583-92.
6. McGauran N, Wieseler B, Kreis J, et al. Reporting bias in medical research-A narrative review. Trials 2010;11:37.
7. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
8. Vedula SS, Bero L, Scherer RW, et al. Outcome reporting in industrysponsored trials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71.
9. Huić M, Marušić M, Marušić A. Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy. PLoS One 2011;6:e25258.
10. Jones CW, Keil LG, Holland WC, et al. Comparison of registered and published outcomes in randomized controlled trials: a systematic review. BMC Med 2015;13:282.
11. Mathieu S, Boutron I, Moher D, et al. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009;302:977-84.
12. Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open 2015;5:e008932.
13. Chan A-W, Pello A, Kitchen J, et al. Association of trial registration with reporting of primary outcomes in protocols and publications. JAMA 2017;318:1709.
14. London AJ. Equipoise in research: integrating ethics and science in human research. JAMA 2017;317:525-6.
15. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of secondgeneration antipsychotics. Am J Psychiatry 2006;163:185-94.
16. Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.
17. Jones CW, Handler L, Crowell KE, et al. Non-publication of large randomized clinical trials: cross sectional analysis. BMJ 2013;347:f6104.
18. Ross JS, Mulvey GK, Hines EM, et al. Trial publication after registration in clinicaltrials. gov: a cross-sectional analysis. PLoS Med 2009;6:e1000144.
19. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registereD in clinicaltrials.Gov. Ann Intern Med 2010;153:158-66.
20. Anand V, Scales DC, Parshuram CS, et al. Registration and design alterations of clinical trials in critical care: a cross-sectional observational study. Intensive Care Med 2014;40:700-22.
21. Hartung DM, Zarin DA, Guise JM, et al. Reporting discrepancies between the clinicaltrials. gov results database and peer-reviewed publications. Ann Intern Med 2014;160:477-83.
22. Li XQ, Yang GL, Tao KM, et al. Comparison of registered and published primary outcomes in randomized controlled trials of gastroenterology and hepatology. Scand J Gastroenterol 2013;48:1474-83.
23. Walker KF, Stevenson G, Thornton JG. Discrepancies between registration and publication of randomised controlled trials: an observational study. JRSM Open 2014;5:204253331351768.
24. You B, Gan HK, Pond G, et al. Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review. J Clin Oncol 2012;30:210-6.
25. Zarin DA, Tse T, Williams RJ, et al. Update on trial registration 11 years after the icmje policy was established. N Engl J Med 2017;376:383-91.